Taghreed Hirz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taghreed Hirz has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- David Brian Sykes
Massachusetts General Hospital, Boston, MA
36 shared publications - Shenglin Mei
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, USA
35 shared publications - Akash Patnaik
University of Chicago, Chicago, IL
31 shared publications - Alexander Swarbrick
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, Australia
17 shared publications - Ani Solanki
University of Chicago
17 shared publications - Anne Kelley
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
17 shared publications
Latest Publications
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Polymorphonuclear neutrophils and cancer : the impact of neutrophils on the sensitivity of lymphoma B cells to cancer therapy
Neutrophiles polymorphonucléaires et cancer : l'impact des neutrophiles sur la sensibilité des cellules de lymphome B aux thérapies anti-cancéreuses: Alors que le rôle des cellules du système immunitaires innées sur la progression tumorale est l'objet d'une investigation croissante, le rôle des neutrophiles sur la sensibilité à la thérapie n'a pas été précédemment décrit. Jusqu’au présent, nous avons effectué des cocultures de neutrophiles et des différentes lignées cellulaires de lymphome non hodgkinien (LNH) en présence de divers agents cytotoxiques ou des thérapies ciblées. Afin d’évaluer l'effet du traitement sur la prolifération cellulaire et la mort des cellules, des marquages CFSE et DAPI ont été effectués respectivement, en utilisant la cytométrie en flux. Les neutrophiles ainsi que les cellules HL60 différenciées avec des propriétés de neutrophiles, ont atténué la sensibilité de cellules de lymphome à des agents anticancéreux in vitro, à la fois dans les modèles 2D et 3D. L'effet protecteur des neutrophiles a été testée in vivo en injectant des cellules de LNH et des neutrophiles chez des souris SCID/CB17 traités avec vincristine. La coinjection de neutrophiles réduit la sensibilité des cellules LNH à la chimiothérapie. Cet effet protecteur a été validé en utilisant des cellules primaires, purifiée à partir de patients atteints de leucémie lymphoïde chronique, exposés à des agents cytotoxiques ou des agents ciblés en présence de neutrophiles autologues. La protection par les neutrophiles est contact dépendante. Elle est médiée par l'interaction de CD11b et ICAM1, exprimé par les neutrophiles et les lymphocytes B, respectivement, et par la molécule d'adhésion CD44. Elle est également dépendante de Mcl1 et est partiellement abrogée par un composé anti-Mcl1
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Polymorphonuclear neutrophils and cancer : the impact of neutrophils on the sensitivity of lymphoma B cells to cancer therapy
Neutrophiles polymorphonucléaires et cancer : l'impact des neutrophiles sur la sensibilité des cellules de lymphome B aux thérapies anti-cancéreuses: Alors que le rôle des cellules du système immunitaires innées sur la progression tumorale est l'objet d'une investigation croissante, le rôle des neutrophiles sur la sensibilité à la thérapie n'a pas été précédemment décrit. Jusqu’au présent, nous avons effectué des cocultures de neutrophiles et des différentes lignées cellulaires de lymphome non hodgkinien (LNH) en présence de divers agents cytotoxiques ou des thérapies ciblées. Afin d’évaluer l'effet du traitement sur la prolifération cellulaire et la mort des cellules, des marquages CFSE et DAPI ont été effectués respectivement, en utilisant la cytométrie en flux. Les neutrophiles ainsi que les cellules HL60 différenciées avec des propriétés de neutrophiles, ont atténué la sensibilité de cellules de lymphome à des agents anticancéreux in vitro, à la fois dans les modèles 2D et 3D. L'effet protecteur des neutrophiles a été testée in vivo en injectant des cellules de LNH et des neutrophiles chez des souris SCID/CB17 traités avec vincristine. La coinjection de neutrophiles réduit la sensibilité des cellules LNH à la chimiothérapie. Cet effet protecteur a été validé en utilisant des cellules primaires, purifiée à partir de patients atteints de leucémie lymphoïde chronique, exposés à des agents cytotoxiques ou des agents ciblés en présence de neutrophiles autologues. La protection par les neutrophiles est contact dépendante. Elle est médiée par l'interaction de CD11b et ICAM1, exprimé par les neutrophiles et les lymphocytes B, respectivement, et par la molécule d'adhésion CD44. Elle est également dépendante de Mcl1 et est partiellement abrogée par un composé anti-Mcl1
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S17 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Supplementary Figure S1. The majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice are de novo resistant to ADT.Supplementary Figure S2. ADT/PI3Ki combination therapy halts prostate tumor growth up to 14 days, followed by development of resistance in majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice.Supplementary Figure S3. PI3Ki treatment with concurrent androgen depletion does not alter proliferation and survival of PTEN/p53-deficient murine PC cells in vitro.Supplementary Figure S4. ADT/PI3K inhibitor combination increases MHC-II and PD-1 expression on TAM within the TME of PTEN/p53-deficient murine PC.Supplementary Figure S5. PD-1 upregulation suppresses phagocytic capacity of activated TAM.Supplementary Figure S6. Ex vivo AD + PI3Ki + PD-1 antibody treatment activates MHCIIlo TAM when co-cultured with PTEN/p53-deficient murine prostate tumor cells.Supplementary Figure S7. The addition of PD-1 blockade to androgen depletion/PI3Ki therapy does not alter phagocytic capacity of PD-1 lo macrophages.Supplementary Figure S8. The combination of androgen depletion, PI3Ki and aPD-1 blockade does not alter phagocytic checkpoint expression on PTEN/p53-deficient prostate tumor cells.Supplementary Figure S9. Androgen depletion, singly and in combination with aPD-1, did not alter phagocytosis activity of inactivated MHC-IIlo/PD-1 lo and MHC-IIlo/PD-1 hi TAM subsets.Supplementary Figure S10. Androgen depletion, not PI3Ki or aPD1, directly enhances TAM activation within the TME of PTEN/p53-deficient PC.Supplementary Figure S11. PI3Ki does not alter phagocytosis/histone lactylation status of MHC-IIlo/PD-1 lo TAM and MHC-IIlo/PD-1 hi TAM.Supplementary Figure S12. PI3Ki inhibits lactate secretion from PTEN/p53-deficient prostate tumor cells within TME.Supplementary Figure S13. Direct ex vivo treatment of TAM with PI3Ki, singly and in combination with PD-1 antibody and/or androgen depletion does not alter their histone lactylation profile.Supplementary Figure S14. ADT + PI3Ki + aPD-1 induces tumor control in 60% of Pb-Cre; PTENfl/fl TP53fl/fl mice.Supplementary Figure S15. Depletion of activated TAM abrogates anti-cancer response elicited by ADT + PI3Ki + PD-1 antibody treatment in the PTEN/p53-deficient murine prostate GEMM tumors.Supplementary Figure S16. Long-term treatment of ADT + PI3Ki + aPD-1 activates Wnt/βcatenin pathway in murine PTEN/p53-deficient GEMM-derived SC1 cells.Supplementary Figure S17. Feedback Wnt/β-catenin-pathway activation within murine PTEN/p53-deficient GEMM-derived PC cells following long-term ADT + copanlisib + aPD1 treatment suppresses phagocytosis via increased histone lactylation within bone marrow derived macrophages (BMDM).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S17 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Supplementary Figure S1. The majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice are de novo resistant to ADT.Supplementary Figure S2. ADT/PI3Ki combination therapy halts prostate tumor growth up to 14 days, followed by development of resistance in majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice.Supplementary Figure S3. PI3Ki treatment with concurrent androgen depletion does not alter proliferation and survival of PTEN/p53-deficient murine PC cells in vitro.Supplementary Figure S4. ADT/PI3K inhibitor combination increases MHC-II and PD-1 expression on TAM within the TME of PTEN/p53-deficient murine PC.Supplementary Figure S5. PD-1 upregulation suppresses phagocytic capacity of activated TAM.Supplementary Figure S6. Ex vivo AD + PI3Ki + PD-1 antibody treatment activates MHCIIlo TAM when co-cultured with PTEN/p53-deficient murine prostate tumor cells.Supplementary Figure S7. The addition of PD-1 blockade to androgen depletion/PI3Ki therapy does not alter phagocytic capacity of PD-1 lo macrophages.Supplementary Figure S8. The combination of androgen depletion, PI3Ki and aPD-1 blockade does not alter phagocytic checkpoint expression on PTEN/p53-deficient prostate tumor cells.Supplementary Figure S9. Androgen depletion, singly and in combination with aPD-1, did not alter phagocytosis activity of inactivated MHC-IIlo/PD-1 lo and MHC-IIlo/PD-1 hi TAM subsets.Supplementary Figure S10. Androgen depletion, not PI3Ki or aPD1, directly enhances TAM activation within the TME of PTEN/p53-deficient PC.Supplementary Figure S11. PI3Ki does not alter phagocytosis/histone lactylation status of MHC-IIlo/PD-1 lo TAM and MHC-IIlo/PD-1 hi TAM.Supplementary Figure S12. PI3Ki inhibits lactate secretion from PTEN/p53-deficient prostate tumor cells within TME.Supplementary Figure S13. Direct ex vivo treatment of TAM with PI3Ki, singly and in combination with PD-1 antibody and/or androgen depletion does not alter their histone lactylation profile.Supplementary Figure S14. ADT + PI3Ki + aPD-1 induces tumor control in 60% of Pb-Cre; PTENfl/fl TP53fl/fl mice.Supplementary Figure S15. Depletion of activated TAM abrogates anti-cancer response elicited by ADT + PI3Ki + PD-1 antibody treatment in the PTEN/p53-deficient murine prostate GEMM tumors.Supplementary Figure S16. Long-term treatment of ADT + PI3Ki + aPD-1 activates Wnt/βcatenin pathway in murine PTEN/p53-deficient GEMM-derived SC1 cells.Supplementary Figure S17. Feedback Wnt/β-catenin-pathway activation within murine PTEN/p53-deficient GEMM-derived PC cells following long-term ADT + copanlisib + aPD1 treatment suppresses phagocytosis via increased histone lactylation within bone marrow derived macrophages (BMDM).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Purpose:Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately 50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is associated with poor prognosis and responsiveness to standard-of-care therapies and immune checkpoint inhibitors. While PTEN loss of function hyperactivates PI3K signaling, combinatorial PI3K/AKT pathway and androgen deprivation therapy (ADT) has demonstrated limited anticancer efficacy in clinical trials. Here, we aimed to elucidate mechanism(s) of resistance to ADT/PI3K-AKT axis blockade, and to develop rational combinatorial strategies to effectively treat this molecular subset of mCRPC.Experimental Design:Prostate-specific PTEN/p53-deficient genetically engineered mice (GEM) with established 150–200 mm3 tumors, as assessed by ultrasound, were treated with either ADT (degarelix), PI3K inhibitor (copanlisib), or anti–PD-1 antibody (aPD-1), as single agents or their combinations, and tumors were monitored by MRI and harvested for immune, transcriptomic, and proteomic profiling, or ex vivo co-culture studies. Single-cell RNA sequencing on human mCRPC samples was performed using 10X Genomics platform.Results:Coclinical trials in PTEN/p53-deficient GEM revealed that recruitment of PD-1–expressing tumor-associated macrophages (TAM) thwarts ADT/PI3Ki combination–induced tumor control. The addition of aPD-1 to ADT/PI3Ki combination led to TAM-dependent approximately 3-fold increase in anticancer responses. Mechanistically, decreased lactate production from PI3Ki-treated tumor cells suppressed histone lactylation within TAM, resulting in their anticancer phagocytic activation, which was augmented by ADT/aPD-1 treatment and abrogated by feedback activation of Wnt/β-catenin pathway. Single-cell RNA-sequencing analysis in mCRPC patient biopsy samples revealed a direct correlation between high glycolytic activity and TAM phagocytosis suppression.Conclusions:Immunometabolic strategies that reverse lactate and PD-1–mediated TAM immunosuppression, in combination with ADT, warrant further investigation in patients with PTEN-deficient mCRPC.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Purpose:Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately 50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is associated with poor prognosis and responsiveness to standard-of-care therapies and immune checkpoint inhibitors. While PTEN loss of function hyperactivates PI3K signaling, combinatorial PI3K/AKT pathway and androgen deprivation therapy (ADT) has demonstrated limited anticancer efficacy in clinical trials. Here, we aimed to elucidate mechanism(s) of resistance to ADT/PI3K-AKT axis blockade, and to develop rational combinatorial strategies to effectively treat this molecular subset of mCRPC.Experimental Design:Prostate-specific PTEN/p53-deficient genetically engineered mice (GEM) with established 150–200 mm3 tumors, as assessed by ultrasound, were treated with either ADT (degarelix), PI3K inhibitor (copanlisib), or anti–PD-1 antibody (aPD-1), as single agents or their combinations, and tumors were monitored by MRI and harvested for immune, transcriptomic, and proteomic profiling, or ex vivo co-culture studies. Single-cell RNA sequencing on human mCRPC samples was performed using 10X Genomics platform.Results:Coclinical trials in PTEN/p53-deficient GEM revealed that recruitment of PD-1–expressing tumor-associated macrophages (TAM) thwarts ADT/PI3Ki combination–induced tumor control. The addition of aPD-1 to ADT/PI3Ki combination led to TAM-dependent approximately 3-fold increase in anticancer responses. Mechanistically, decreased lactate production from PI3Ki-treated tumor cells suppressed histone lactylation within TAM, resulting in their anticancer phagocytic activation, which was augmented by ADT/aPD-1 treatment and abrogated by feedback activation of Wnt/β-catenin pathway. Single-cell RNA-sequencing analysis in mCRPC patient biopsy samples revealed a direct correlation between high glycolytic activity and TAM phagocytosis suppression.Conclusions:Immunometabolic strategies that reverse lactate and PD-1–mediated TAM immunosuppression, in combination with ADT, warrant further investigation in patients with PTEN-deficient mCRPC.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 3: Gating strategy for enrichment of TREM2+SPP1+ macrophages. Labels above the flow plots refer to the parent population in the percentages are of the parent gate.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 3: Gating strategy for enrichment of TREM2+SPP1+ macrophages. Labels above the flow plots refer to the parent population in the percentages are of the parent gate.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 1: Metadata for samples involved in this study
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 1: Metadata for samples involved in this study
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 6: Spatial architecture of tumor associated macrophages in prostate cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 6: Spatial architecture of tumor associated macrophages in prostate cancer.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Tumor-associated macrophages (TAM) are a transcriptionally heterogeneous population, and their abundance and function in prostate cancer is poorly defined. We integrated parallel datasets from single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to reveal the dynamics of TAMs in primary and metastatic prostate cancer. Four TAM subpopulations were identified. Notably, one of these TAM subsets was defined by the co-expression of SPP1+ and TREM2+ and was significantly enriched in metastatic tumors. The SPP1+/TREM2+ TAMs were enriched in the metastatic tumor microenvironment in both human patient samples and murine models of prostate cancer. The abundance of these SPP1+/TREM2+ macrophages was associated with patient progression-free survival. Spatially, TAMs within prostate cancer bone metastases were highly enriched within the tumor region, consistent with their protumorigenic role. Blocking SPP1 in the RM1 prostate cancer mouse model led to improved efficacy of anti–PD-1 treatment and increased CD8+ T-cell infiltration in tumor. These findings suggest that targeting SPP1+ TAMs may offer a promising therapeutic strategy and potentially enhance the effects of immune checkpoint inhibition in advanced prostate cancer.Implications:This study expands our understanding of the diverse roles of macrophage populations in prostate cancer metastases and highlights new therapeutic targets.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Tumor-associated macrophages (TAM) are a transcriptionally heterogeneous population, and their abundance and function in prostate cancer is poorly defined. We integrated parallel datasets from single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to reveal the dynamics of TAMs in primary and metastatic prostate cancer. Four TAM subpopulations were identified. Notably, one of these TAM subsets was defined by the co-expression of SPP1+ and TREM2+ and was significantly enriched in metastatic tumors. The SPP1+/TREM2+ TAMs were enriched in the metastatic tumor microenvironment in both human patient samples and murine models of prostate cancer. The abundance of these SPP1+/TREM2+ macrophages was associated with patient progression-free survival. Spatially, TAMs within prostate cancer bone metastases were highly enriched within the tumor region, consistent with their protumorigenic role. Blocking SPP1 in the RM1 prostate cancer mouse model led to improved efficacy of anti–PD-1 treatment and increased CD8+ T-cell infiltration in tumor. These findings suggest that targeting SPP1+ TAMs may offer a promising therapeutic strategy and potentially enhance the effects of immune checkpoint inhibition in advanced prostate cancer.Implications:This study expands our understanding of the diverse roles of macrophage populations in prostate cancer metastases and highlights new therapeutic targets.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 4: Nano-string DSP spatial expression of proteins
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 4: Nano-string DSP spatial expression of proteins
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 2: Heterogeneity of tumor associated macrophage localized prostate cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 2: Heterogeneity of tumor associated macrophage localized prostate cancer.